Ph 1b Data for Tegavivint + Osimertinib combo in 1L EGFR-Mutated NSCLC Announced
“These promising results provide important early clinical evidence supporting tegavivint’s differentiated mechanism of action and its potential to address one of the fundamental limitations of targeted cancer therapy: the persistence of drug-tolerant tumor cells,” said Rahul Aras, Ph.D., President and Chief Executive Officer of Iterion Therapeutics. “We are particularly excited by the depth of tumor reduction, complete responses and survival observed in this study, together with the favorable tolerability profile of the combination. We believe these data provide important clinical validation for targeting β-catenin signaling and support the continued development of tegavivint in combination with targeted cancer therapies.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000